Dr Lentzsch on Results for Linvoseltamab in Heavily Pretreated R/R Myeloma

Suzanne Lentzsch, MD, PhD, professor of medicine, director, Multiple Myeloma and Amyloidosis Program, Columbia University Herbert Irving Comprehensive Cancer Center, discusses the data from the phase 1/2 LINKER-MM1 study (NCT03761108) evaluating linvoseltamab in patients with relapsed/refractory multiple myeloma.
Results presented at the 2024 EHA Congress showed that at a median follow-up of 14.3 months, linvoseltamab demonstrated significant efficacy in inducing deep and durable responses in patients with relapsed/refractory multiple myeloma, including those in high-risk subgroups.
The study included 117 patients who received a median of 5 prior lines